Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.

Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8.

View in: PubMed

subject areas

Adenocarcinoma
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
Humans
Male
Middle Aged
Prostatic Neoplasms
Quality of Life
Suramin

authors with profiles

Walter M. Stadler
Mark J. Ratain